CClinicalTrials.gg
CompletedNCT06180460Updated Oct 8, 2025

CALM: Managing Distress in Malignant Brain Cancer

An interventional study of CALM and Treatment as usual in Brain Tumor, Brain Metastases and Brain Cancer, sponsored by Virginia Commonwealth University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-08.

Sponsored by Virginia Commonwealth University · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to test an empirically supported psychotherapeutic intervention, Managing Cancer and Living Meaningfully (CALM), compared to treatment as usual (TAU) in those with malignant brain cancer diagnoses.

02

Conditions studied

  • Brain Tumor
  • Brain Metastases
  • Brain Cancer
  • Metastatic Lung Cancer
  • Metastatic Breast Cancer
  • Metastatic Melanoma
  • Metastatic Colon Cancer
  • Metastatic Kidney Cancer

Keywords

  • Service Members
  • Veterans
03

In context

Brain Neoplasms

1,960 studies on the registry are indexed under Brain Neoplasms; 516 are open to participants now.

This study's enrollment of 60 is above the median of 40 across 1,458 interventional studies indexed under Brain Neoplasms.

Browse Brain Neoplasms studies →

Lead sponsor

Virginia Commonwealth University is the lead sponsor of 641 studies on the registry; 82 are open to participants now.

Of its 88 completed or terminated interventional studies of FDA-regulated products, 62 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Self-reported diagnosis of brain metastasis (bMET) or a malignant primary brain tumor (PBT; specifically grade III or IV and CNS diffuse large B cell lymphomas)*
  • At least 2-weeks post-surgical resection or biopsy of the brain (if applicable)
  • Score > 20 on the TICS
  • Reported elevated depression (PHQ-9 score ≥ 10) OR death anxiety symptoms (DADDS score ≥ 15)
  • Ability to read, speak, and understand English
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion criteria

Exclusion Criteria:

  • Major communication difficulties which would prohibit the psychotherapeutic interaction
  • Inability to meet with the interventionist via an electronic device for telehealth intervention sessions
  • Inability to understand and provide informed consent
  • Prisoners
  • Medical, psychological, or social condition that, in the opinion of the principal investigator, may increase the participant's risk of adverse events and/or prohibit the individual's participation in the intervention.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Managing Cancer and Living Meaningfully (CALM)

    CALM optimally consists of six individual sessions of 45 to 60 minutes, delivered over a three- to six-month period. CALM sessions address four broad and interrelated domains found to be important and relevant in this population: (1) symptom management and communication with healthcare providers, (2) changes in personal relationships, (3) sense of meaning and purpose, and (4) the future, hope and mortality.

    Behavioral: CALM

  • Placebo comparator
    Treatment as Usual (TAU)

    Treatment as usual (TAU) for managing distress in brain cancer involves being provided a list of local / national resources (e.g., psychologist, social worker, or other mental health providers) if an individual chooses to seek treatment for the distress they are experiencing.

    Behavioral: Treatment as usual

Interventions

  • BehavioralCALM

    The CALM intervention is a supportive-expressive therapy that is administered by CALM trained clinicians in a particular style.

  • BehavioralTreatment as usual

    Treatment as usual includes a list of local / national resources (e.g., psychologist, social worker, or other mental health providers) if an individual chooses to seek treatment for the distress they are experiencing.

06

What researchers measure

Primary outcomes

  1. Assess the feasibility of the CALM intervention- Screening Rate

    Percent of interested individuals who undergo screening

    Time frame: Day 0

  2. Assess the feasibility of the CALM intervention- Consent Rate

    Percent of eligible individuals who consent to the trial

    Time frame: Day 0

  3. Assess the feasibility of the CALM intervention- Intervention Retention Rate

    Percent of consented individuals who complete the CALM intervention

    Time frame: 3 months

  4. Assess the feasibility of the CALM intervention- Post-Intervention Questionnaire Completion Rate

    Percent of consented individuals who complete post-intervention questionnaires

    Time frame: 3 months

  5. Assess the feasibility of the CALM intervention- Follow-up Questionnaire Completion Rate

    Percent of consented individuals who complete follow-up questionnaires

    Time frame: 6 months

  6. Assess the acceptability of the CALM intervention- Participant Satisfaction

    Satisfaction ratings from participants during exit interview (e.g., Rate your overall benefit on a scale of 1-5).

    Time frame: 4 months

  7. Assess the acceptability of the CALM intervention- Participant Recommendation Ratings

    Percent of participants who would recommendation CALM to others will be assessed during the exit interview (e.g., Would you recommend this program to others?)

    Time frame: 4 months

07

Study locations

1 site
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06180460
Lead sponsor
Virginia Commonwealth University
Collaborators
United States Department of Defense
Responsible party
Sponsor
First posted
Dec 22, 2023
Start date
Nov 10, 2023
Primary completion
Sep 30, 2025
Completion
Sep 30, 2025
Last update
Oct 8, 2025

Study contacts

Ashlee Loughan, Ph.D
principal investigator · Virginia Commonwealth University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion